Abstract 65P
Background
In healthy cells rather than being evenly distributed phosphatidylserine (PS) and phosphatidylethanolamine (PE) are found preferentially in the inner leaflet of the plasma membrane. Unlike normal cells, tumor cells lose the ability to maintain aminophospholipid asymmetry and expose PS naturally which promotes tumor growth and immune suppression by mechanisms that are not established. Since both PS and PE are co-regulated by the same transporters, in the case of PE translocation it might also serve as a specific lipid biomarker diagnostic the prognostic value of which is yet to be determined. We aimed to investigate whether hypoxia and low pH characteristics of tumor microenvironment (TME) might promote PE translocation on the surface leaflet of cancer cells membranes.
Methods
Ovarian cancer cells OVCAR-4 were incubated under standard (pH=7.5, O2=21%) and TME modeling conditions (pH=5.8, О2=1%) following with a two-step staining with PE-specific biotinylated Ro09 and streptavidin conjugated with Alexa Fluor 405. Propidium iodide (PI) staining was conducted to justify plasma membrane integrity. Visualization of PE on living OVCAR-4 cells was performed with the use of laser confocal microscopy.
Results
Under normoxic conditions a signal from PE was not detected on the surface of intact OVCAR-4 cells. However, under TME conditions cells were positive for PE staining, but not for PI, demonstrating that PE is translocated from the inner to the outer leaflet of cancer cell membrane.
Conclusions
Our results show that non apoptotic externalization of aminophospholipids in cancer cells has become a subject of great interest due to correlation with innate immune suppression and promotion of tumor growth. We propose that TME-driven surface exposure of PE, a second abundant phospholipid in cell membrane, coincides with constitutive PS externalization and can serve as a potential TME-specific therapeutic target and/or diagnostic tool for ovarian and other types of cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Research Laboratory \"Biomarker\", Institute of Fundamental Medicine and Biology, Kazan Federal University.
Funding
This work has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract